Recent advances in AAV vectorology have allowed recombinant AAV (rAAV) vectors to be used for human clinical trials. However, the basic biology of AAV vectors is still not well understood. This has been a major limitation for the full exploitation of the usefulness of rAAV vectors. Despite numerous research activities focusing on the tissue tropism and applications for rAAV vectors, the fate of rAAV genomes in vivo and the mechanisms of AAV genome conversion have not been well characterized. Preclinical clinical studies suggest that a disturbing dose of IxlO14 vector genomes may be necessary for a human subject. Our hypothesis is that rAAV genome instability seriously reduces its efficiency. The single stranded (ss). AAV genome can be recognized by host cells as DNA damage signal which leads to a cascade of AAV genome loss/degradation immediately after uncoating. Such mechanism will not allow substantial free ss AAV to exist in the host for an extended period. The limiting step for efficient rAAV transduction is therefore more likely to be intracellular processing of AAV virions and both ss and double stranded AAV genome loss/degradation. In addition, the random integration of AAV genomes is a major concern for AAV vectors. To address this issue, we plan to quantify rAAV integration frequency. Hence, our specific aims are 1). To study the conversion of AAV genome from single stranded DNA to double stranded form. 2). To study the stability of double stranded AAV genomes 3). To quantify the frequency of rAAV integration in vivo. The successful execution of these specific aims will help identify new strategies for improving rAAV transductionefficiency and utilizingrAAV vectors safely.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
7R01HL080789-05
Application #
7745481
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Skarlatos, Sonia
Project Start
2006-02-15
Project End
2011-08-31
Budget Start
2010-01-01
Budget End
2011-08-31
Support Year
5
Fiscal Year
2010
Total Cost
$327,713
Indirect Cost
Name
Temple University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
057123192
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Yao, Yiwen; Wu, Junlu; Zhou, Hao et al. (2018) A deficiency in cathelicidin reduces lung tumor growth in NNK/NTHi-induced A/J mice. Am J Cancer Res 8:1190-1199
Xiao, Weidong; Gao, Guangping; Ling, Chen et al. (2018) Impact of neutralizing antibodies against AAV is a key consideration in gene transfer to nonhuman primates. Nat Med 24:699
Wang, Minqian; Firrman, Jenni; Zhang, Liqing et al. (2017) Apigenin Impacts the Growth of the Gut Microbiota and Alters the Gene Expression of Enterococcus. Molecules 22:
Li, Zhenzhou; Li, Ying; Zhang, Li et al. (2017) Reduced Myocardial Reserve in Young X-Linked Muscular Dystrophy Mice Diagnosed by Two-Dimensional Strain Analysis Combined with Stress Echocardiography. J Am Soc Echocardiogr 30:815-827.e9
Wang, Qizhao; Dong, Biao; Pokiniewski, Katie A et al. (2017) Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors. Mol Ther Methods Clin Dev 4:149-158
Wang, Qizhao; Wu, Zhongren; Zhang, Junping et al. (2017) A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors. Mol Ther Methods Clin Dev 7:146-156
Arango-Argoty, Gustavo; Singh, Gargi; Heath, Lenwood S et al. (2016) MetaStorm: A Public Resource for Customizable Metagenomics Annotation. PLoS One 11:e0162442
Wang, Qizhao; Firrman, Jenni; Wu, Zhongren et al. (2016) High-Density Recombinant Adeno-Associated Viral Particles are Competent Vectors for In Vivo Transduction. Hum Gene Ther 27:971-981
Wang, Q; Dong, B; Firrman, J et al. (2016) Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment. Gene Ther 23:597-605
Kelich, Joseph M; Ma, Jiong; Dong, Biao et al. (2015) Super-resolution imaging of nuclear import of adeno-associated virus in live cells. Mol Ther Methods Clin Dev 2:15047

Showing the most recent 10 out of 21 publications